Oncolytics Biotech Inc T.ONC

SP

[lonc17]

It's not hard to read the tea leaves here. The share price is cratering weeks before ONC's "big reveal" of key data. And their number 1 prospect declined to make a suitable offer during an exclusivity period. 

I suppose Bracelet will be just another on the long list of failed trials for ONC.

Fortunately for Matt, he has the miracle CR from Goblet Panc to keep the gravy train running for another few years. 

Unfortunately for any long term shareholder, this will most likely mean another reverse split.

I sincerely hope I am wrong but things are looking very grim for ONC.

[westcoast1000]

Ionc, How do you draw this supposition from any tea leaves? "I suppose Bracelet will be just another on the long list of failed trials for ONC." We have not knowledge of these results other than what can be drawn from the previous trial.  We also have no knowledge of what has or has not been offered, or what is still in play. ONCY would be foolish to accept any offer without

[lonc17]

The share price begain a precipitous decline shortly after Matt disclosed that Pfizer's exclusivity period had ended. Many investors have taken this as a strong signal that the Bracelet trial will be a dud.  

[Snowdrift]

List of failed trials???  They've had nothing but successes. Big pharma would not hang around for years with a company that had a series of failed trials. Pretty lame attack on your part.

[lonc17]

List of failed trials (partial list, going from memory): Prostate Glioblastoma Melanoma Head and Neck Sarcoma Lung Cancer Bladder Ovarian Is that enough?  I could probably find a few more, like the children's solid tumour trial that was never once mentioned by ONC after failure.  Tough to keep track of, I know, because ONC changed the name of their product from Reolysin to

[westcoast1000]

That story ignores some basic facts. All those trials were as monotherapy, assuming direct lysis of cancer cells is the right mechanism for pela success. What is the company doing now? NOT THAT APPROACH.  It is now being tested with really surprising and remarkable success as an I/O agent in combination therapies. Ionc's comments would be fair and reasonable if we were still doing

[Noteable]

No lonc17 that is not enough. I certaintly don't recall any of those trials being registered as clinical trials other than the head and neck trial that had been run in Russia. Blame Brad Thompson for that one. So since you've been quite adamant in your criticism of ONCY, I ask that you to post the clinical trial numbers found at clinical.trials.gov, so that we can accurately judge your

[Noteable]

And then show me where those trials failed.

[lonc17]

https://clinicaltrials.gov/ct2/results?cond=&term=Reolysin&cntry=&state=&city=&dist=   Gosh, notable, that took me about 5 seconds to find these trials.  Any concluded trial that does not progress to the next phase is by definition a failed trial. Funny that new investors may never have heard of Reolysin. Brilliant move on ONC's part, even if it did

[Noteable]

Each study that was listed was using pelareorep as a monotherapy. What was discovered was that neither pelareorep or PD-(L)1 immune checkpoint inhibitors work well as a single agent monotherapy. What also was discovered was that pelareorep + PD-(L)1 immune checkpoint inhibitors when combined were synergistic and that the 2 agents together worked better than either alone.  How many times

[Lesalpes29]

Good recap. I want you to join the BOD to help them during the actual negociations with the BP. GL